Delivery Order 36F79724D0101-36C24925F0120
Award Date
2/24/25
Potential Completion Date
3/2/25
Potential Value
$335K
Federal Agency
Veterans Integrated Service Network 9
Awardee
Bristol-Myers Squibb Company
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to the U.S. Department of Veterans Affairs (VA). The contract, valued at $310,953.57, was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on December 13, 2024. The work is primarily performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey, and the delivery order has a completion date of January 12, 2025. This award is a delivery order...
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to patient ENR-018564. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9). The contract is a firm fixed price delivery order with a ceiling value of $310,935.67 and a performance period ending on January 5, 2025. This order is placed against...
This is a firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical firm, for the supply of BREYANZI, an advanced chimeric antigen receptor (CAR) T cell therapy. The contract, valued at $335,042.65, supports the VA's Veterans Health Administration and is part of Bristol-Myers Squibb's larger Federal Supply Schedule (FSS) contract with the VA, worth up to $12.28 billion. The contract is not...
The U.S. Department of Veterans Affairs (VA) awarded a $335,042.65 firm fixed price delivery order contract to Bristol-Myers Squibb Company for the provision of the BREYANZI chimeric antigen receptor (CAR) T cell therapy. This order is a part of Bristol-Myers Squibb's larger $12.28 billion Federal Supply Schedule (FSS) contract (36F79724D0101) with the VA, which covers a range of pharmaceutical and hematology-related products. The contract supports the VA's mission of providing advanced...
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy for treating non-Hodgkin lymphoma, to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on a firm fixed price basis with a potential value of $310,935.67. The contract has a completion date of June 10, 2024 and is not associated with...
The U.S. Department of Veterans Affairs (VA) awarded a delivery order contract to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the provision of two chimeric antigen receptor (CAR) T cell therapies: BREYANZI and ABECMA. The contract, valued at $314,322.29, is a firm fixed price delivery order under Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the VA Veterans Health Administration. The work is primarily performed at Bristol-Myers Squibb's...
This is a federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, for its BREYANZI chimeric antigen receptor (CAR) T cell therapy. The $310,935.67 firm fixed price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9 and has an ultimate completion date of October 31, 2024. The award is not a set-aside contract. Bristol-Myers Squibb supplies the BREYANZI treatment, which is used to treat...
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy used to treat non-Hodgkin lymphoma. The $310,953.67 firm fixed-price delivery order has an ultimate completion date of August 30, 2024. This award is a call against Bristol-Myers Squibb's existing Federal Supply Schedule...
The U.S. Department of Veterans Affairs (VA) awarded a firm-fixed-price delivery order contract to Bristol-Myers Squibb Company for the procurement of the cancer immunotherapy drug BREYANZI. The contract, valued at $335,042.65, has an ultimate completion date of May 14, 2025 and is placed under the company's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA. This contract does not carry a set-aside designation, reflecting Bristol-Myers Squibb's status as a large...
This is a delivery order award under a Federal Supply Schedule (FSS) contract (ID: 36F79724D0101) held by Bristol-Myers Squibb Company with the Department of Veterans Affairs Veterans Health Administration. The award, valued at $310,953.57, is for the delivery of two chimeric antigen receptor (CAR) T cell immunotherapies - BREYANZI and ABECMA - to various Veterans Integrated Service Networks (VISNs). BREYANZI is used to treat certain types of non-Hodgkin lymphoma, while ABECMA is a B-cell...